Objective: Abnormal activations of neural networks implicated in auditory stimuli processing are hypothesized to generate auditory hallucinations (AH) in schizophrenia spectrum disorders. Because repetitive transcranial magnetic stimulation (rTMS) has the potential to modulate neural network activity, several studies have explored its use in treating medication-resistant AH, with mixed results in small-to-medium patient samples. Our aim is to apply a metaanalytic approach to exploring the efficacy of rTMS in treating medication-resistant AH.
F or patients suffering from SSD, AH are common and disabling psychotic experiences. The pathophysiology underlying AH is still elusive: with data pointing toward hyperactivity of the neural networks regulating speech, one hypothesis posits inner speech perception abnormalities, 1 while another suggests that there is abnormal auditory cortex activation. 2 As suggested by a fMRI case study, these 2 hypotheses are not mutually exclusive and some data supports that they may even be related. 3 The inner speech perception abnormalities are often considered to stem from a default of monitoring of inner states, 4 with the result, in the case of AH, of mislabelling of inner speech as nonself. This hypothesis is supported by functional brain imaging studies showing extensive activation of neural networks overlapping with those involved in auditory verbal imagery (that is, imagining another person talking to them), but failing to involve key regions involved in internal source monitoring. [5] [6] [7] [8] Using artificial neural network simulations, it has been suggested that antipsychotic medication relieves AH by globally decreasing the activation level of a hyperactive auditory neural network. 9 Antipsychotic medication represents the treatment of choice for AH and other positive psychotic symptoms, but has several significant adverse effects and is ineffective in up to 30% of patients. 10 Several brain stimulation approaches are currently being investigated as novel therapeutic interventions.
A noninvasive technique for stimulating the brain in ambulant, awake humans is rTMS. A stimulating coil applied to the scalp creates a high-intensity magnetic pulse that passes painlessly through the soft tissues and induces an electric current in the underlying neurons of the cerebral cortex. Initially used to map the human cortex 11 in a less invasive way than the direct electrical stimulation pioneered by Dr Wilder Penfield in the 1930s, rTMS was also observed to have neuropsychiatric effects. Although the exact mechanisms underlying rTMS are still controversial, several studies have shown that the excitability of the stimulated cortex diminishes with low-frequency stimulation (1 Hz or less) 12 and increases with high-frequency stimulation (usually 10 Hz and more). 13, 14 Areas of research include the extent of transsynaptic propagation of the rTMS (for example, it has been shown that frontal cortical stimulation releases dopamine in the caudate and striatum 15, 16 ) and the durability of the change in cortical excitability. 12 Several research groups have tried to reduce AH by diminishing left temporoparietal cortex excitability with low-frequency rTMS, a brain area involved in speech perception. These industry-independent studies showed divergent results and lacked power because of a small number of patients enrolled. A metaanalytic methodology will make it possible to increase the power and the reliability of their results.
Our aim is to verify whether rTMS is an effective treatment for AH in SSD. Thus the principal outcome will be the reduction of AH using rTMS in SSD patients. The secondary outcome, meant to verify whether rTMS has a specific or broad effect, is the reduction of positive psychotic symptoms in rTMS-treated patients.
Our study will differ from a recent metaanalysis 25 in at least 3 dimensions: our focus is on the clinical pertinence of rTMS and not the research implications of the results; our inclusion criteria are different, with consequential differences in the final sample; and, the methodology differs both in the outcome measures and the statistical treatment of data. As discussed below, the results will show both significant differences and interesting replications.
If it proves efficacious, it will be one of the few somatic treatments of schizophrenia based on a priori etiological hypotheses. Moreover, the relatively benign adverse effect profile 17, 18 compares positively with antipsychotic medication and the alternative adjuvant treatments of AH.
Method
Based on our research hypothesis, we outlined a predetermined methodology described below. All papers were screened independently for these criteria and disagreements were solved by discussion. 
Database Search

Inclusion Criteria
To be included in the metaanalysis, studies had to meet the following criteria: human experimental studies of rTMS treatment, patients with a diagnosis of SSD, and treatment of AH.
Exclusion Criteria
Based on what are currently considered the valid parameters for an effective rTMS trial, we excluded studies that: were not randomized or lacked placebo control, had less than 3 treatment sessions, lacked a quantitative report of AH (that is, use of a valid psychometric scale), the coil was not placed over the left temporoparietal cortex, or rTMS was not given at low frequency (1 Hz or less).
The last 2 requirements are necessary because the rTMS effect is specific to location and frequency: the primary stimulation area is a small cortical region and rTMS probably has opposite effects at low and high frequencies.
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Statistical Analysis
All data collection was done using Microsoft Excel. Where appropriate, data from subscales have been pooled to provide one mean and SD through D-Stat. 19 Data were then gathered in Comprehensive Meta-Analysis, 20 version 2, for metaanalytic assessment.
Data Acquisition
We extracted the data and resolved differences by discussion. For follow-up losses of more than 10% of the initial population, the ITT and last observation carried forward corrections were used.
In cases where unpublished data were of interest to us, the authors of the clinical trials were contacted by email to obtain the most detailed information available.
Regarding the main outcome, several scales for assessing AH are used in the literature and might be reported in scientific papers. We extracted information, in order of decreasing preference, from the HCS, AHRS, SAH scale, PSYRATS-AH, and PANSS-AH. The HCS is a visual-analog scale personalized for each subject following a narrative description of AH at the beginning of the study. The baseline is by definition set at 10, possible choices start at 0 (no hallucinations) to 20 (increased AH). The AHRS is quite different as it gives a composite score by summing the following dimensions: hallucination frequency, number of different speaking voices, perceived loudness, vividness, attentional salience (the degree to which hallucinations captured the attention of the patient), length of hallucinations (single words, phrases, sentences, or extended discourse), and degree of distress. The PSYRATS-AH follows the same multidimensional construct (11 dimensions). The SAH is a composite scale of the frequency, suffering, belief, and behavioural influences of AH. Finally, the PANSS-AH is one of the items of PANSS, and a unidimensional measure of AH severity.
For the secondary outcome, we extracted information in order of decreasing preference, from the SAPS, PANSS-Positive, PANSS-Total, and PANSS-General Scales (from more specific to more general).
Data from each study were transformed to z scores to perform a 2´2 factorial ANOVA using the following formula:
where SS is the sum of square, s is the SD of the trial, and m is the mean of the trial. The 2´2 ANOVA was performed to determine treatment effect over time for AH and psychotic symptoms. When baseline AH was fixed by scale design (for example, HCS baseline is 10 by definition), the baseline SD was assumed to be equal to the end-point SD for statistical calculations.
In this metaanalytic assessment, we have used a 2-stem model. 21 Based on the availability of reported statistics, and in order of decreasing preference, we computed the ES by exact calculation from each subject, by author-reported ES, by estimation from the F value or by estimation from mean score changes or, finally, by estimation from mean scores at the study end-point. The ES was calculated by comparison of the active rTMS treatment with the sham treatment. When calculating mean changes (start and end-point scores), the SD was conservatively estimated to be the average of start and end-point SD.
To ensure independence in the database, each study could contribute only once to the overall ES estimate. Afterwards, we looked into possible moderating clinical and methodological variables.
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As part of this prospective methodology, we defined a set of a priori metaregressions for ES as a function of the length of treatment (days), total number of stimuli, intensity of rTMS (expressed as a percentage of the MT), and size of the experimental group. We further compared the ES estimates as a function of the study design (crossover, compared with parallel arms), quality of placebo (sham coil, compared with tilted active coil), and type of AH scale (change of AH, compared with degree of AH).
Quality of Studies
Trial quality was assessed based on Cochrane's checklist from the Cochrane reviewers' handbook. 23 The checklist involved 6 criteria: allocation of concealment, blinding of participant, blinding of investigator (that is, we are considering the blinding of the outcome rater and not of the rTMS provider, who is often unblinded because of the nature of rTMS sham technique), blinding of outcome assessment, completeness of follow-up, and ITT. We excluded the ITT variable from the checklist when there was less than a 10% attrition rate (all cases). One short report missed one criteria 24 and the other studies obtained a score of 5 out of 5.
Results
Descriptive Statistics
The total number of published and unpublished studies retrieved by our database search and cross-referencing was 265. Among these, only 26 matched the inclusion criteria: 124 did not study patients with schizophrenia; 50 were literature reviews; 31 did not measure AH; 12 were nontreatment explorations of cortical excitability over the motor cortex; 8 were editorials, letters, or comments; and 31 studies were rejected for multiple reasons (often being completely unrelated to the study question). One study protocol was registered in the Current Control Trials database and could not be linked to any publication. The principal investigator clarified by email that the study was never done. Finally, a paper reporting metaanalysis of rTMS for schizophrenia was identified more recently 25 and will be discussed below.
Among the 26 studies included, only 15 were double-blind randomized studies. Three studies did not report any measure for AH and one study 26 was excluded as it was a preliminary report and all patients were discussed in a more recent publication. 27 One study 28 presented significant methodological discrepancies with the remaining studies: the stimulation site was stereotaxically determined following individual fMRI detection of inner-speech regions. Moreover, only 5 out of 12 patients tolerated the complete procedure, with the rest being stimulated in locations inferred from the results of the first 5 patients. In addition, the AH scale (PSYRATS-AH) was transformed and translated without any reported validation. Hence, we excluded this study from our analysis (decision different from Aleman et al's 25 metaanalysis).
Synopsis of the 10 Studies Retained
All 10 studies matching both inclusion and exclusion criteria studied 1 Hz rTMS as an adjuvant treatment for medication-resistant AH. No studies were funded by rTMS manufacturers and no significant conflicts of interest were reported. 
Magnitude of Difference
We used a random effect model, recommended for metaanalyses combining crossover and parallel design studies 37 ( Figure 1 ).
The end-point metaanalysis with a random effect model yielded a homogeneous (Q = 13.022; P = 0.162) and a statistically significant Hedges' g = 0.514, P = 0.001. File drawer analysis with classical fail-safe N was later performed, and suggested that we would need to locate 38 additional studies showing no benefit from rTMS treatment to reverse our findings (that is, 2-tailed P value to exceed 0.050). Given our extensive search of the literature, it is improbable that there would be such a large number of unpublished studies (Table 2) .
Moderating Variables
The medium effect estimate was robust, with less than 20% variation by study design, quality of sham, or specific scales (AHRS, compared with HCS). We found a greater ES variation when comparing AH change scales and AH scales measuring the degree of hallucination.
Fixed-effects metaregression analyses of the Hedges' g ES as a function of total number of stimulations, rTMS intensity (percentage of MT), and duration of treatment (days) failed to show any statistically significant relation (all Ps > 0.100).
ANOVA
A 2´2 ANOVA with time and group as factors was performed for the 9 studies with available data on AH.
To control for the effect of treatment over time, mean AH scores reported by different researchers were transformed into z scores using their SD to assess a pooled variance. The 2´2 factorial ANOVA revealed a significant time´treatment interaction (F = 7.66, df = 1, 32, P < 0.01), showing that, over time, there is a significant change in AH scores for schizophrenia patients treated with rTMS.
The same method was applied to a 2´2 ANOVA on positive psychotic symptoms scores. In this analysis, we were able to obtain data only from 6 studies ( Table 3) . The analysis revealed a nonsignificant time´treatment interaction, a significant time effect (F = 12.03; df = 1, 20, P = 0.01), and a significant treatment group effect (F = 5.93; df = 1,20, P = 0.05).
Discussion
The main result of this metaanalysis is a medium ES explaining a decrease in AH in the population of medication-resistant patients suffering from SSD, as a result of 1 Hz rTMS treatment of the left temporoparietal cortical region.
The study population was suffering from significant AH that were considered 
Limitations
Placebo quality is problematic in rTMS because of the difficulty of reproducing the noise and the scalp sensation (including superficial muscle contractions) of the active treatment. The initial method of producing a placebo effect was to tilt the coil at 45°or 90°. However, this method clearly unmasks blinding for the treating clinician and might unmask it for patients who had previously been treated with rTMS or for those in a crossover design. The more recent methods involve using a completely similar sham coil. We analyzed the different placebo methods separately and found no significant difference in ES reports, which reduces the probability that the observed effect was due to the unmasking of blinding. This limitation if commonly found at different levels in nonpharmacological research (for example, electroconvulsive therapy and psychotherapy), thus telling us more about the limitations of the double-blind paradigm in informing clinical practice outside pharmacotherapy.
A significant limitation of this study is the concomitant pharmacotherapy in all subjects. Several pharmacological treatments may interfere with treatment response, either by modifying cortical excitability, by preventing the transsynaptic transmission of TMS, or by interfering with the cerebral plasticity effects induced by rTMS. The concomitant medication was not always described, and separate analyses were rarely performed. Brunelin et al's 38 study noted that, while none of the responders were receiving benzodiazepines or anticonvulsants, the 3 nonresponders were receiving one of those 2 treatments. Thus it may well be that the effect of the active treatment is underestimated in subjects receiving multiple medications. Alternatively, these results do not tell us anything about the rTMS antipsychotic efficacy in unmedicated subjects. This would be a promising line of future research, notably given the more benign side effects of rTMS.
An important factor in metaanalytic heterogeneity was the type of AH assessment. While the majority of AH scales have proven psychometric reliability (with the exception of the SAH, for which psychometric properties are not reported), they probably measure different constructs. The HCS is probably more sensitive to change and AHRS provide more detailed assessments of dimensions of hallucinations than the PANSS-AH. These differences in measuring AH may explain the differences in treatment effects between studies: the HCS seems more sensitive to rTMS effects on AH, while most studies using AHRS reported negative results. The global ESs followed the same trend.
Finally, given that the rTMS effects seem to persist for significant periods (more than 15 weeks for most responders in Hoffman et al 27 ), the crossover studies might have been biased by a carry-over effect. We suggest that this design 
Figure 1 ES of AH reduction between rTMS and sham at the end of trial
Random effect model (n = 10) studies should be avoided in further studies of rTMS in schizophrenia.
Should we consider that a metaanalysis is an experimental trial with a specific population sample (n = number of studies), the replication of the Aleman et al 25 work is relevant. Our metaanalysis confirms globally their findings, while using different inclusion and exclusion criteria, resulting in a sample differing in 2 out of 10 studies: the number of studies documented in Table 1 of their quantitative review, do not match the number of studies included in their analysis. More specifically, for instance, the trial by Lee et al 32 reports of left and right stimulation, but it is not documented in their data extraction. As argued in the results section, we decided to exclude the study on stereotaxic rTMS by Schonfeldt-Lecuona et al 28 ;
using a different methodology: different ES extraction strategies, use of ANOVA and metaregressive strategies. Our ANOVA analysis is unique in contrasting a specific effect on AH with a lack of significant global effect on psychotic symptoms, obtaining more robust results: with respect to our a priori methodology, we were able to report more analyses and results and use more robust statistical analyses. As a result, our sample showed a homogenous ES, while their results are weakened by significant heterogeneity, offering a clinically oriented answer to the question of the efficacy of rTMS in AH, as the present study is aimed at a clinically relevant discussion, while the Aleman et al 25 study had a stronger research emphasis.
Insights Into the Pathophysiology of AHs
While several well-established treatments in psychiatry (and medicine in general) have evolved from serendipitous discoveries, the application of rTMS to AH followed from specific pathophysiologic hypotheses regarding the nature of AH and the expected effects of rTMS. Hence, the positive and specific results of this metaanalysis are strong arguments in support of the hypothesis that AH are related to abnormal hyperactivity of neural networks related to audition and (or) speech processing. The inability to identify a dose-response relation by a metaregression analysis of total stimulations, intensity of stimulations or duration of treatment suggests that there may be mediating mechanisms explaining the observed therapeutic effect. Moreover, the phenomenology of AH shows a greater complexity than our available models. Consequently, stating that the physiopathology underlying AH is only a hyperactivity of the left superior temporal region (the underlying cortical region of the temporoparietal stimulation location) is an oversimplification that is serving neither the scientist, the clinician, nor the patient.
Clinical Implications
Firstly, we must keep in mind the possibility that other stimulating parameters or locations may show equal or superior efficacy. 32 The localizing technique can be improved by using stereotaxic neuronavigational tools and functional neuroimaging. Priming with subthreshold, brief high-frequency rTMS enhances the depressant effects of low-frequency stimulation of the motor cortex, 39 opening the possibility that such high-frequency priming will also have an enhancing effect on AH suppression. Even with these limitations, our metaanalysis found an ES (Hedges' g) of 0.514, which is considered to be in the medium range. As a comparison, a recent metaanalysis showed that clozapine is superior to typical antipsychotics in treatmentresistant schizophrenia with an ES total of 0.48 (Brief Psychiatric Rating Scale). 40 However, the exact clinical meaning of significant AH improvement is yet to be clarified. We have little information on its repercussions on functioning, subjective well-being, negative symptoms, and positive symptoms. Hoffman et al 27 reports lasting effects, but the rest fail to follow the patients sufficiently to tell us anything about medium or long-term outcome. Our study failed to identify a comparable effect of rTMS on psychotic symptoms, which may imply that rTMS is a specific treatment for AH.
Even though long-term outcomes are generally related to negative and cognitive symptoms, being able to diminish a patient's suffering as a result of hallucinations is still an important therapeutic goal, albeit not necessarily the only one. Moreover, when studying the case of clozapine for resistant schizophrenia, one notices that the effect of clozapine on negative symptoms takes longer to show significant clinical responses than that on positive symptoms. Given the short duration of follow-up for the vast majority of rTMS studies, these negative results should be interpreted as lack of proof of efficacy, rather than a proof of lack of efficacy.
In conclusion, this metaanalysis brings an additional level of evidence supporting rTMS use in patients suffering from schizophrenia with medication-resistant AH. Given the scarcity of evidence for other somatic treatments in this group of patients, we consider this result to be highly clinically relevant. In fact, other than clozapine, we are not aware of any somatic therapy for treatment-resistant schizophrenia that is supported by 2 metaanalyses and several double-blind randomized controlled trials. 32 reported PANSS-P to be improved in the active group (F = 7.41; df = 2; P = 0.002), but lacks information to estimate an ES.
Résumé : Doit-on traiter les hallucinations auditives par stimulation magnétique transcranienne répétitive? Une méta-analyse Objectif : Les activations anormales des réseaux neuraux impliquées dans le traitement des stimuli sonores produisent hypothétiquement des hallucinations auditives (HA) dans les troubles du spectre de la schizophrénie. Parce que la stimulation magnétique transcranienne répétitive (SMTr) a le potentiel de moduler l'activité du réseau neural, plusieurs études en ont exploré l'utilisation pour traiter les HA réfractaires aux médicaments, avec des résultats partagés dans des échantillons de patients de taille modeste à moyenne. Nous visons à appliquer une approche méta-analytique afin de sonder l'efficacité de la SMTr pour traiter les HA réfractaires aux médicaments.
Méthode : Une recherche d'études comparant la SMTr de faible fréquence (1-Hz) sur le cortex temporo-pariétal gauche pour feindre la stimulation chez des patients souffrant de HA réfractaires aux médicaments a été menée dans les bases de données électroniques. Notre recherche a été complétée par une vérification de concordance des articles, menée au site Web des Current Controlled Trials, et par une communication directe avec les chercheurs concernés.
Résultats : Sur les 265 résumés possibles, 6 essais sur groupes parallèles, à double insu et contrôlés par placebo, et 4 essais croisés contrôlés, tous randomisés, satisfaisaient aux critères d'inclusion et d'exclusion (total n = 232). La principale mesure de résultat (l'effet du traitement actif sur les HA au terme du traitement) a été testée par un modèle à effets aléatoires et a atteint une estimation de l'ampleur de l'effet homogène significative (g de Hedges = 0,514; P = 0,001; 95 % IC, 0,225 à 0,804; Q = 13,022; P = 0,162).
Conclusions :
Nous acons constaté que la SMTr de faible fréquence sur le cortex temporo-pariétal gauche a une action d'ampleur d'effet moyenne sur les HA réfractaires aux médicaments. Ce résultat a des implications pour comprendre la pathophysiologie des symptômes psychotiques (spécifiquement les HA) et soutient l'utilisation de la SMTr comme méthode de traitement complémentaire chez les patients souffrant de HA réfractaires au traitement.
